Increase in the frequency of p16(INK4) gene inactivation by hypermethylation in lung cancer during the process of metastasis and its relation to the status of p53

Clinical Cancer Research

Volumn 6, Issue 11, 2000, Pages 4307-4313

  Seike, M ^a   Gemma, A ^a   Hosoya, Y ^a   Hemmi, S ^a   Taniguchi, Y ^a   Fukuda, Y ^a   Yamanaka, N ^a   Kudoh, S ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53; CDKN2B PROTEIN, HUMAN; CELL CYCLE PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 2B; TRANSCRIPTION FACTOR; TUMOR SUPPRESSOR PROTEIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; FEMALE; GENE FREQUENCY; GENE INACTIVATION; HUMAN; LUNG CANCER; LUNG CARCINOGENESIS; MALE; METASTASIS; METHYLATION; PRIORITY JOURNAL; PROMOTER REGION; TUMOR SUPPRESSOR GENE; ADENOCARCINOMA; DNA METHYLATION; GENETICS; LUNG TUMOR; MIDDLE AGED; MUTATION; PATHOLOGY; SQUAMOUS CELL CARCINOMA;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; CELL CYCLE PROTEINS; CYCLIN-DEPENDENT KINASE INHIBITOR P15; DNA METHYLATION; FEMALE; GENES, P16; GENES, P53; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM METASTASIS; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEINS;

EID: 0033626213     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. p53 Mutation in human cancers
2. Wild-type but not mutant p53 suppresses the growth of human lung cancer cells bearing multiple genetic lesions
3. Stability of p53 tumor suppressor gene mutations during the process of metastasis and during chemotherapy
4. Mutations and altered expression of p16(CKD2) in human cancer
5. Mechanism of inactivation of CDKN2 and MTS2 in non-small cell lung cancer and association with advanced stage
6. Mutations in the p16INK4(/MTS1/CDKN2), p15(INK4B/MTS2), and p18 genes in primary and metastatic lung cancer
7. Molecular analysis of the cyclin-dependent kinase inhibitor genes p15(INK4B/MTS2), p16(INK4/MTS1), p18 and p19 in human cancer cell lines
8. The FHIT gene 3p14.2 is abnormal in lung cancer
9. Allelic deletion analysis of the FHIT gene predicts poor survival in non-small cell lung cancer
10. D type cyclins associate with multiple protein kinases and the DNA replication and repair factor PCNA
11. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4
12. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers
13. A cell cycle regulator potentially involved in genesis of many tumor types
14. 5' CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16(CDKN2/MTS1) in human cancers
15. Mechanisms of p16(CDKN2/MTS1) inactivation in non small-cell lung cancers
16. p16(INK4) a promoter is hypermethylated at a high frequency in esophageal adenocarcinomas
17. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers
18. CDKN2 gene silencing in lung cancer by DNA hypermethylation and kinetics of p16INK4 protein induction by 5aza 2'deoxycytidine
19. Hypermethylation-associated inactivation indicates a tumor suppressor role for p15(INK4B)
20. Association of CDKN2A(p16)/CDKN2B(p15) alterations and homozygous chromosome arm 9p deletions in human lung carcinoma
21. Correlation between methylation status of the p16/CDKN2 gene and the expression of p16 and Rb proteins in primary non-small cell lung cancers
22. Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis
23. Codeletion of p15 and p16 genes in primary non-small cell lung carcinoma
24. Intragenic mutations of the p16(INK4), p15(INK4B) and p18 genes in primary non-small-cell lung cancers
25. hSmad5 gene, a human hSmad family member: Its full length cDNA, genomic structure, promoter region and mutation analysis in human tumors
26. FHIT mutations in human primary gastric cancer
27. Methylation-specific PCR: A novel PCR assay for methylation status of CpG islands
28. Alterations of Rb pathway (Rb-p16INK4-cyclin D1) in preinvasive bronchial lesions
29. Alterations of the p16-pRb pathway and the chromosome locus 9p21-22 in non-small-cell lung carcinomas: Relationship with p53 and MDM2 protein expression
30. Correlation of abnormal RB p16INK4a, and p53 expression with 3p loss of heterozygosity, other genetic abnormalities, and clinical features in 103 primary non-small cell lung cancers
31. p16 Inactivation in small-sized lung adenocarcinoma: Its association with poor prognosis
32. In situ detection of the hypermethylation-induced inactivation of the p16 gene as an early event in oncogenesis
33. Inactivation of the INK4A/ARF locus frequently coexists with TP53 mutations in non-small cell lung cancer
34. Expression of p16INK4a/p16α and p19ARF/p16β is frequently altered in non-small cell lung cancer and correlates with p53 overexpression
35. Methylation of the multi tumor suppressor gene-2 (MTS2, CDKN1, p15INK4B) in childhood acute lymphoblastic leukemia
36. Hypermethylation of p15/INK4b/MTS2 gene is differentially implicated among non-Hodgkin's lymphomas